Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Nephrology | Urology | Family Medicine
Disease Category: Prostate Cancer
Location: United States, ND
Clinical Trial Details
Research Study Summary
A research study for patients who have been diagnosed with metastatic, castrate-resistant prostate cancer
A study to evaluate a new way of potentially treating prostate cancer using a new vaccine that may help cells from your own body to recognize and kill the cancer cells.
Patient Inclusion Criteria:
- Men 18 – 85 years of age with documented asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer
- Life expectancy >1 year
- Chemotherapy naïve
- No significant cardiovascular disease
- No contraindication for vaccinia immunization
Patient Exclusion Criteria:
- Chemotherapy: Concomitant use of chemotherapy is not allowed during the Treatment phase (approximately 5 months) of this trial.
- Anti-cancer radionuclides: Concomitant use of anti-cancer radionuclides is not allowed during the Treatment phase of this trial.
- Secondary hormonal therapies: Concomitant use of supplementary hormonal treatments is not allowed during the Treatment phase of this trial.
- Corticosteroids: Concomitant chronic use of systemic corticosteroids is not allowed during the Treatment phase of the study. The use of inhaled corticosteroids, nasal sprays, and topical creams for small body areas is allowed.
To Learn more
Date Last Changed:
July 18, 2013
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these